Biogen Inc. (NASDAQ:BIIB) is a leading biotechnology company focused on discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Known for its multiple sclerosis (MS) treatments, Biogen faces stiff competition from pharmaceutical giants like Roche and Novartis in the neurology space.
On February 6, 2026, BMO Capital adjusted its rating for Biogen to "Market Perform," maintaining a "hold" action. At that time, the stock price was $201.13. BMO Capital also raised Biogen's price target from $165 to $196, reflecting a more optimistic outlook for the company's future performance.
Biogen reported fourth-quarter 2025 earnings per share (EPS) of $1.99, surpassing the Zacks Consensus Estimate of $1.61. However, this was a 42% decline from the previous year. The company's total revenue for the quarter was $2.28 billion, exceeding the Zacks Consensus Estimate of $2.21 billion, despite a 7% year-over-year decline.
The revenue decline was attributed to weaker sales of key MS drugs like Tecfidera and Tysabri, and the spinal muscular atrophy (SMA) drug Spinraza. However, increased sales from newer drugs such as Leqembi, Skyclarys, and Zurzuvae partially offset this decline. The stock gained following an optimistic 2026 adjusted EPS guidance, projected to be between $15.25 and $16.25, above consensus expectations.
Biogen's stock is currently priced at $201.18, reflecting an increase of 8.53% or $15.82. The stock has fluctuated between a low of $184.60 and a high of $202.41 today, with the latter marking its highest price over the past year. The company has a market capitalization of approximately $29.51 billion, with a trading volume of 3,378,325 shares on the NASDAQ.
